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Biology
	■ SARS-CoV-2 is single-stranded RNA, enveloped 
virus that likely spread to humans from a zoonotic 
source, possibly bats or pangolins1.
	■ It is believed to spread from person to person via 
respiratory droplet nuclei2.
	■ Other routes of infection (e.g. contact, enteric) 
are possible as the virus can persist on surfaces 
and is shed in feces, but it is unclear if these are 
significant means of spread.2,3
	■ There is evidence of transmission by asymptomatic 
individuals4.
	■ The virus binds to the ACE2 receptor on type II 
pneumocytes. However, the role of Angiotensin 
Converting Enzyme Inhibitors and Angiotensin 
Receptor Blockers (ARBs) as treatments or risk 
factors for disease is unclear5. 
	■ The reported incubation time is 3-12 days with a 
median duration of viral shedding of 20 days6,7.
	■ There is evidence that the virus changes over time. 
There may be multiple strains of SARS-CoV-2 in 
circulation8.
Epidemiology
Characteristics such as the attack rate (% of 
individuals in an at-risk population who acquire the 
infection), R0 (R naught, the expected number of 
cases directly generated by one case in a population 
where all individuals are susceptible to infection), 
and case fatality rate (CFR, % of infected individuals 
who die) are contextual. That is, they depend on 
factors such as testing rate, population density, and 
control strategies that vary from location to location. 
These factors may also change over time. Table 1 
summarizes reported epidemiologic characteristics of 
SARS-CoV-29.
Table 1: Reported epidemiologic characteristics of 
SARS-CoV-2.
Attack rate: 30-40% (community, in China)
R0: 2-4 (lower with containment)
Case fatality rate 1.5% USA, 3.4% overall 
worldwide
Incubation time 3-14 days
Viral shedding Median 20 days
Clinical Presentation
Symptoms may vary from mild cough to fulminant 
respiratory failure. Positive tests have also been 
obtained from asymptomatic patients. Table 2 lists 
the estimated frequency of symptoms observed to 
date10:
Table 2: Frequency of Symptoms in COVID-19
Symptom Percent of patients with symptom
Cough 50-80%
Fever 85% (only 45% febrile on 
presentation)
Fatigue 69.6%
Dyspnea 20-40%
URI symptoms 15%
GI symptoms (nausea, 
vomiting, diarrhea)
10%
Diagnosis and Management of COVID-19 Disease
SARS-CoV-2 is a novel coronavirus that was identified in late 
2019 as the causative agent of COVID-19 (aka coronavirus 
disease 2019). On March 11, 2020, the World Health 
Organization (WHO) declared the world-wide outbreak of 
COVID-19 a pandemic. This document summarizes the most 
recent knowledge regarding the biology, epidemiology, 
diagnosis, and management of COVID-19. 
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Laboratory Findings
The following lab abnormalities have been observed 
in patients with COVID-1910:
	■ Complete blood count: normal WBC, leukopenia, 
lymphopenia (80%+), thrombocytopenia
	■ Chemistries: elevated BUN/creatinine, elevated 
AST, ALT, and Total bilirubin
	■ Inflammatory markers: normal or low procalcitonin, 
high C-reactive protein and ferritin
	■ Miscellaneous: elevated D-dimer, interleukin -6, 
and lactate dehydrogenase
Imaging:
Imaging findings are frequently absent on 
presentation and should not be used for diagnosis of 
COVID. Many patients have normal imaging at the 
time of presentation, but the following abnormalities 
have been reported (Figure 1)10:
	■ Chest X-ray: bilateral, peripheral, patchy opacities
	■ Chest CT scan: bilateral ground glass opacities, 
crazy paving, and consolidation. Not routinely 
recommended to avoid unnecessary exposure 
during transport
	■ Point-of-care ultrasound: B-lines, pleural line 
thickening, consolidations with air bronchograms. 
Assessment of cardiac function is also useful
Figure 1: COVID-19 Imaging. (A) CXR showing bilateral 
peripheral opacities, (B) Chest CT showing diffuse 
ground glass with a peripheral predominance, (C) point 
of care lung ultrasound showing predominance of 
B-lines in patients with COVID-19. Images courtesy of 
Dr. Nick Mark.
Diagnostic Testing and Reporting:
Lack of availability has hampered testing to date, but 
testing capacity is increasing quickly. The following 
recommendations have been made regarding 
diagnostic testing and reporting11,12.
	■ Send nasopharyngeal swab for SARS-CoV-2 
polymerase chain reaction testing (RT-PCR). 
Check with your local facility regarding test 
characteristics, including sensitivity and specificity
	■ Differentiating SARS-CoV-2 from other circulating 
respiratory viruses is important, particularly 
Influenza, therefore consider testing of usual 
respiratory pathogens. Co-infection has also been 
reported
	■ Do not order sputum induction
	■ Avoid bronchoscopy unless absolutely indicated 
 ◆ If indicated, follow current recommendations 
for bronchoscopy in suspected COVID-19 
patients as recommended by the American 
Association for Bronchology and Interventional 
Pulmonology13
	■ PFTs or spirometry are not indicated in these 
patients. In addition, ATS and American College 
of Occupational and Environmental Medicine has 
recommended against doing routine outpatient 
PFTs for concerns of spread
	■ Notify your local health department of positive 
cases
Isolation and Infection Control for Confirmed and 
Suspected Cases:
Recommendations for isolation and infection control 
are evolving as more is learned about the SARS-
CoV-2 virus. Current best practices include:
	■ Place all suspected patients in droplet masks 
during assessment and when in transit
	■ If cohorting is required due to resource limitation, 
keep patients 2 meters apart in a single room
	■ Restrict visitors
	■ Try to avoid room entry unless essential; try to 
move equipment (e.g. IV pumps) out of the room
	■ Hand hygiene: 20+ seconds with soap and or 60-
95% alcohol containing hand gel
	■ Use appropriate PPE in the correct sequence, 
including14: 
 ◆ Standard precautions
 ◆ Contact precautions 
 ◆ Droplet precautions with eye protection
 ◆ PLUS airborne precautions for aerosolizing 
procedures such as intubation, extubation, non-
invasive positive pressure ventilation (NIPPV), 
open circuit suctioning, bronchoscopy, and 
aerosol treatments
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	■ N95 masks must be fit tested
	■ All Healthcare professionals must be trained in how 
to properly don, use, and doff PPE in a manner to 
prevent self-contamination
	■ If available, consider powered air-purifying 
respirator (PAPRs) or controlled air purifying 
respirators (CAPRs). 
 ◆ Use of tight-fitting respirators require fit testing, 
but use of loose-fitting respirators does not 
require fit testing15
General Treatment Recommendations
The following treatment strategies are recommended 
based on experience to-date. Of note, these are 
suggestions and should not replace clinical judgement 
at the bedside.
	■ Fluid-sparing resuscitation
	■ Empiric antibiotics if suspicion for secondary 
infection
	■ Due to concerns for aerosol spread, nebulizers 
should be converted to MDIs
	■ WHO has not recommended against the use of 
Non-steroidal anti-inflammatory agents. Clinicians 
should consider alternatives if concerns exist
	■ Initiating or discontinuing ACE-I and ARBs have 
been an area of intense discussion. The American 
College of Cardiology, American Heart Association 
and Heart Failure Society of America’s joint 
statement recommends against discontinuing 
ACE-I and ARBs in patients with COVID-19
	■ Monitor for and treat cardiomyopathy and 
cardiogenic shock which have been reported as 
a late complication of COVID-19. Point-of-care 
ultrasound may be useful in identifying patients 
with this complication
	■ Corticosteroids are not recommended except when 
required for other indications such as asthma or 
COPD exacerbations, refractory shock or evidence 
of cytokine storm
Management of Hypoxemic Respiratory Failure
These are suggestions and should not replace clinical 
judgement at the bedside.
	■ Oxygen by nasal cannula OR simple mask OR non-
rebreather masks
	■ Consider early intubation to avoid use of 
aerosolizing NIPPV and emergent intubations
	■ Use rapid-sequence intubation. Avoid bag-mask 
valve if possible due to risk of droplet spread
	■ Avoid direct laryngoscopy to distance provider 
from patient. Use video laryngoscopy where 
possible
	■ Connect suction and capnography in advance to 
avoid circuit breaks
	■ Minimize circuit breaks and use high-efficiency 
particulate air (HEPA) filters between endotracheal 
tubes and CO2 detectors
	■ Use lung-protective ventilation strategies per 
ARDSnet protocol. Prone and paralyze as needed
	■ Patients will likely require a prolonged duration of 
mechanical ventilation
	■ Extracorporeal Membrane Oxygenation (ECMO) 
can be considered but is associated with a high 
mortality rate16
	■ Monitor for and treat cardiomyopathy and 
cardiogenic shock which have been reported as 
a late complication of COVID-19. Point-of-care 
ultrasound as well as BNP levels may be useful in 
identifying patients with this complication
 ◆ In a recent case series from Washington, 33% of 
patients developed cardiomyopathy17
Investigational Therapies
Information on registered clinical trials for COVID-19 
in the United States is available at: https://
clinicaltrials.gov/
	■ No US Food and Drug Administration (FDA)-approved 
drugs specifically for the treatment of patients with 
COVID-19 currently exist. Drugs currently approved 
for other indications as well as investigational drugs 
are being studied in clinical trials17 
	■ FDA approved drugs that may be used off-label
 ◆ Chloroquine or Hydroxychloroquine—blocks viral 
entry into the endosome; in vitro data suggests 
some utility but data from RCTs is lacking
	■ Investigational agents available in the U.S. Avoid 
prophylactic use
 ◆ Remdesivir—anti-viral nucleotide analog 
	■ Other drugs
 ◆ Lopinavir/ritonavir—anti-viral protease inhibitors; 
recent negative RCT19
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 ◆ Tocilizumab—IL-6 inhibitor and may have a role in 
cytokine storm and for patients in shock
Prognosis
Based on experience in China, 80% of patients have 
mild symptoms, 15% moderate, and 5% severe 
(requiring mechanical ventilation). Most patients 
deteriorate gradually with a median of 9 days from 
symptom onset to ICU admission. Pregnant women 
and children appear to have a better prognosis. The 
following factors have been associated with worse 
outcomes:
	■ Increasing age
	■ Comorbidities including diabetes, cardiovascular 
disease (including hypertension), and chronic lung 
disease
	■ Higher admission sequential organ failure 
assessment (SOFA) score
	■ Laboratory abnormalities: elevated D-dimer, 
ferritin, and troponin
Control Strategies
The following strategies are recommended to slow 
the rate of SARS-CoV-2 spread: 
	■ Contact tracing
	■ Social /Physical distancing
	■ Quarantine of suspected cases and exposed 
individuals
	■ Travel restrictions
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